Evidence map›Paper›PMID 36974487›Full record

ReviewJournal of medical screening2023

Overview of organisational methods of primary cervical lesion screening programmes that use human papillomavirus testing.

Agathe Marchadier, Laura Bezannier, Stéphanie Barré-Pierrel, Antoine Manceau, Audrey A Abadie, Bruno Detournay

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of medical screening, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Agathe MarchadierInstitut National du Cancer, Boulogne Billancourt, France.
Laura BezannierCemka, Bourg-la-Reine, France.ORCID 0000-0003-4201-4032
Stéphanie Barré-PierrelInstitut National du Cancer, Boulogne Billancourt, France.ORCID 0000-0002-0313-6232
Antoine ManceauPwC Advisory - Healthcare & Pharmaceuticals Life-Sciences, Neuilly-sur-Seine, France.
Audrey A AbadiePwC Advisory - Healthcare & Pharmaceuticals Life-Sciences, Neuilly-sur-Seine, France.
Bruno DetournayCemka, Bourg-la-Reine, France.
Cemka-Eval (France) · FRInstitut National du Cancer · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many factors need to be considered when planning and managing a screening programme for the early detection of cervical cancer (CC). A non-systematic international review of the organisation of CC screening using high-risk human papillomavirus (HPV-HR) testing, aimed at identifying the organisational methods of these programmes, was conducted with a view to supporting the future of the French system in the context of the transition to HPV-HR testing. In countries where HPV testing has been implemented or planned, the initial reflection process has provided an opportunity to rethink the previous (cytological) screening organisation. Despite considerable differences between countries, a nationally or regionally centralised organisational model appears to be the preferred option in most countries. This model is based on a national/regional structure tasked with all invitations, reminders, follow-up and coordination, centralised laboratories integrating both biology and pathology laboratories, and a unified information system integrated with routine health management tools used by health practitioners and nurses. Besides quality considerations, grouped purchasing makes it possible to implement a public procurement policy that includes price negotiations with suppliers. Discussions around the introduction of HPV testing have resulted in most countries reviewing or creating information systems and quality assurance processes. While the WHO seems to recommend the systematic use of vaginal self-sampling, very few countries have considered this option. More and more countries are planning to implement vaginal self-sampling, but no clear organisational model has emerged from the countries where it has been implemented to date.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsCervix UteriEarly Detection of CancerFemaleHuman Papillomavirus VirusesHumansMass ScreeningPapillomaviridaeVaginal SmearsCervical cancerhuman papillomavirusmass screeningorganisational innovation

Identifiers

PMID36974487
PMCPMC10399092
OpenAlexW4361190563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.